A Balance Sheet Built to Absorb AccidentsWide moat

Johnson & Johnson (JNJ) — moat facet

J&J absorbed about $12 billion of talc charges in two years and still raised its dividend each year.

A business that sells medicines and devices will have accidents: a product liability verdict, a failed trial, a patent struck down early. The fourth part of J&J's moat is that it can absorb them without changing course, and the evidence is the last decade.

Net debt ($bn)17.420226.4202312.1202427.8202528.2Jun 2026J&J Forms 10-K FY2023 and FY2025; Form 10-Q Q2 2026
The cushion was drawn down in 2025.

The accidents have been large. J&J recorded talc charges of approximately $7.0 billion in 2023 and $5.1 billion in 20241, paid a $0.8 billion Auris judgment in January 20262, and still had about $0.9 billion of opioid settlements to pay at the end of June 20263. Through all of it the company raised its dividend every year, reaching 64 consecutive increases in April 20264.

What absorbs the blows is cash flow. Operating cash flow was $24,530 million in 20255, and free cash flow about $19.7 billion6. The company's credit standing adds a margin: a 2024 report noted that J&J was one of two public companies still holding a AAA rating from Standard and Poor's, though with a negative outlook7.

That margin has been used. Net debt rose from $12.1 billion at the end of 2024 to $27.8 billion at the end of 20258, and total debt rose to 37.0% of total capital from 34.0%9. The borrowing paid for acquisitions, principally Intra-Cellular.

The balance sheet also shrinks the share count over time, from 2,812.9 million diluted shares in 201510 to 2,429.4 million in 202511, and the Kenvue separation showed J&J can reshape itself at scale.

The list of legal matters is long enough to need a balance sheet like this. Beyond talc, J&J has resolved hernia mesh litigation through a 2021 settlement covering 3,729 Physiomesh cases12, paid the Auris judgment, and faces an antitrust class action over Tracleer samples in which the trial was scheduled for March 202613. A company this size in this industry will always be defending something; the question is only whether it can pay without changing strategy.

It also carries a tax bill from the last reform to its end. The final $2.5 billion payment of the transition tax on foreign earnings imposed by the 2017 tax law was made in 202514, so a cash outflow of that size will not recur in 2026.

The balance sheet has also been used to reshape the company. The Kenvue exchange offer retired 190,955,436 J&J shares worth $31.4 billion15, and the orthopaedics separation is expected to create a standalone company with an investment-grade profile16.

This is a wide advantage being drawn on. A company that can commit $5.5 billion to end a fifteen-year litigation17 while buying businesses and raising its dividend has a cushion worth protecting. The falsifier is net debt: above $35 billion without a matching rise in cash flow would say the cushion that absorbs accidents is being spent on purchases.

Moat trajectory: Narrowing

Net debt more than doubled in 2025 to fund acquisitions.

The number that tests this moat
Reported
Net debt, latest quarter
$28.2bn (Q2 2026; $12.1bn end-2024)

The cushion that absorbs accidents; above $35bn without higher cash flow would mean it is being spent on purchases.

Source: Johnson & Johnson Form 10-Q, Q2 2026 ↗
Aspects of the moat
DIG DEEPER 01
Twenty-Four Billion Dollars of Operating Cash
J&J has generated between $18.8 billion and $24.5 billion of operating cash every year for a decade, including the year it lost 41% of a major drug.
DIG DEEPER 02
Sixty-Four Dividend Increases in a Row
J&J has raised its dividend 64 years in a row and pays it from about 63% of free cash flow.
DIG DEEPER 03
The Share Count Keeps Falling
J&J has retired about one share in seven since 2015, half of it by trading away Kenvue.
DIG DEEPER 04
Kenvue: What Was Given Away and What Was Kept
J&J gave Kenvue the consumer brands and kept the talc lawsuits they produced.
⚠ Threats to the moat
⚠ THREAT 01
Net Debt More Than Doubled in 2025
J&J's net debt went from $12.1 billion to $27.8 billion in a single year of buying.
⚠ THREAT 02
A AAA Rating With a Negative Outlook
The rating agency that gives J&J its rare AAA rating has had it on negative outlook since the Abiomed and Shockwave deals.
References
  1. ReportedJ&J recorded talc charges of approximately $7.0 billion in 2023 and $5.1 billion in 2024, paid a $0.8 billion Auris judgment in January 2026, and still had about $0.9 billion of opioid settlements to pay at the end of June 2026.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
  2. ReportedJ&J recorded talc charges of approximately $7.0 billion in 2023 and $5.1 billion in 2024, paid a $0.8 billion Auris judgment in January 2026, and still had about $0.9 billion of opioid settlements to pay at the end of June 2026.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
  3. ReportedJ&J recorded talc charges of approximately $7.0 billion in 2023 and $5.1 billion in 2024, paid a $0.8 billion Auris judgment in January 2026, and still had about $0.9 billion of opioid settlements to pay at the end of June 2026.
    Johnson & Johnson Form 10-Q for the quarter ended 28 June 2026 - segment income, talc, net debt, repurchases and equity. — Q2 2026 · publ. 23 July 2026 · source ↗
  4. ReportedThrough all of it the company raised its dividend every year, reaching 64 consecutive increases in April 2026.
    Johnson & Johnson announcement of its 64th consecutive annual dividend increase, Form 8-K exhibit 99.3. — April 2026 · publ. 14 April 2026 · source ↗
  5. ReportedOperating cash flow was $24,530 million in 2025, and free cash flow about $19.7 billion.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - financial statements and notes: income statement, balance sheet, cash flows, equity, segment income, acquisitions and geographic assets. — FY2025 · publ. 11 February 2026 · source ↗
  6. ReportedOperating cash flow was $24,530 million in 2025, and free cash flow about $19.7 billion.
    Johnson & Johnson fourth-quarter and full-year 2025 results release, Form 8-K exhibit 99.1 - adjusted earnings, free cash flow and 2026 guidance. — FY2025 · publ. 21 January 2026 · source ↗
  7. Third-party estimateThe company's credit standing adds a margin: a 2024 report noted that J&J was one of two public companies still holding a AAA rating from Standard and Poor's, though with a negative outlook.
    The Motley Fool, only two public companies still hold a AAA credit rating - S&P reaffirmed J&J's AAA with a negative outlook (third-party report, October 2024). — 2024 · publ. 24 October 2024 · source ↗
  8. ReportedNet debt rose from $12.1 billion at the end of 2024 to $27.8 billion at the end of 2025, and total debt rose to 37.0% of total capital from 34.0%.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: rebate accrual tables, research and development, cost of products sold, debt and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
  9. ReportedNet debt rose from $12.1 billion at the end of 2024 to $27.8 billion at the end of 2025, and total debt rose to 37.0% of total capital from 34.0%.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: rebate accrual tables, research and development, cost of products sold, debt and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
  10. ReportedThe balance sheet also shrinks the share count over time, from 2,812.9 million diluted shares in 2015 to 2,429.4 million in 2025, and the Kenvue separation showed J&J can reshape itself at scale.
    Johnson & Johnson Form 10-K for fiscal 2017 - segment sales and income for 2015-2017, net earnings and dividends per share. — FY2017 · publ. February 2018 · source ↗
  11. ReportedThe balance sheet also shrinks the share count over time, from 2,812.9 million diluted shares in 2015 to 2,429.4 million in 2025, and the Kenvue separation showed J&J can reshape itself at scale.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - financial statements and notes: income statement, balance sheet, cash flows, equity, segment income, acquisitions and geographic assets. — FY2025 · publ. 11 February 2026 · source ↗
  12. ReportedBeyond talc, J&J has resolved hernia mesh litigation through a 2021 settlement covering 3,729 Physiomesh cases, paid the Auris judgment, and faces an antitrust class action over Tracleer samples in which the trial was scheduled for March 2026.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
  13. ReportedBeyond talc, J&J has resolved hernia mesh litigation through a 2021 settlement covering 3,729 Physiomesh cases, paid the Auris judgment, and faces an antitrust class action over Tracleer samples in which the trial was scheduled for March 2026.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
  14. ReportedThe final $2.5 billion payment of the transition tax on foreign earnings imposed by the 2017 tax law was made in 2025, so a cash outflow of that size will not recur in 2026.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: consolidated sales, volume and price, geography, the three wholesalers, rebate accruals, costs, R&D and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
  15. ReportedThe Kenvue exchange offer retired 190,955,436 J&J shares worth $31.4 billion, and the orthopaedics separation is expected to create a standalone company with an investment-grade profile.
    Johnson & Johnson Form 10-K for fiscal 2023 - the Kenvue initial public offering and exchange offer, and 2021-2022 restated to continuing operations. — FY2023 · publ. February 2024 · source ↗
  16. ReportedThe Kenvue exchange offer retired 190,955,436 J&J shares worth $31.4 billion, and the orthopaedics separation is expected to create a standalone company with an investment-grade profile.
    Johnson & Johnson announcement of its intent to separate the Orthopaedics business (DePuy Synthes), Form 8-K exhibit 99.3. — October 2025 · publ. 14 October 2025 · source ↗
  17. ReportedA company that can commit $5.5 billion to end a fifteen-year litigation while buying businesses and raising its dividend has a cushion worth protecting.
    Johnson & Johnson announcement of a proposed resolution of ovarian talc litigation, Form 8-K exhibit 99.1. — July 2026 · publ. 27 July 2026 · source ↗
Sources
Generated September 24, 2026